Vanda Pharma VNDA has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings ...

In the past 60 days, estimates for Vanda’s 2025 loss per share have narrowed from 53 cents to 35 cents. With a sound cash position and some clinical milestones expected later this year, investor ...